Unknown

Dataset Information

Rituximab for interstitial pneumonia with autoimmune features at two medical centres.


ABSTRACT:

Objectives

Many patients with interstitial lung disease (ILD) have autoimmune manifestations but do not meet criteria for a systemic rheumatic disease. A subset meets criteria for interstitial pneumonia with autoimmune features (IPAF) and have ILD requiring therapy. We conducted a multicentre observational study to examine the use of rituximab (RTX) in IPAF.

Methods

Patients from Mass General Brigham (MGB) and University of Chicago Medicine (UCM) were included if they were ≥18 years old, met the 2015 classification criteria for IPAF and were treated with RTX. Clinical improvement was defined as improvement in four out of four domains at 1 year after RTX initiation: documented clinician global assessment; oxygen requirement; need for respiratory-related hospitalization; and s

SUBMITTER: D'Silva KM 

PROVIDER: S-EPMC8570147 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature